哺乳动物雷帕霉素靶蛋白抑制药的心血管作用研究进展

哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）是一种非典型的丝氨酸／苏氨酸激酶，属于磷酯酰肌醇3激酶相关激酶（phosphatidylinositol kinase—related kinases，PIKKs）家族。mTOR抑制药已上市的有雷帕霉素（Rapamycin／Sirolimus，RAP）及依维莫司（Everolimus，RAD001），主要用于器官移植的抗排异反应。

mTOR信号传导通路相关蛋白与肿瘤治疗

哺乳动物雷帕霉素靶蛋白基因位于1p36.2上,其mRNA翻译后的蛋白质有2549个氨基酸残基,其分子结构复杂,分子质量为289kDa。mTOR是一种丝/苏氨酸蛋白激酶,通过调节细胞周期、蛋白质合成、细胞能量代谢等多种通路发挥重要的生理功能,在细胞增殖、生长、分化过程中起着中心调控点的作用。此外,mT0R在肿瘤的形成、发展、转移过程中也起着重要作用。在一些肿瘤中可见mTOR通路的持续活动的现象。到目前为止,mTOR抑制药作为靶向性抗肿瘤药物被有效地应用于肾癌及肝癌等治疗。因此,mTOR信号通路的深入研究对肿瘤的靶向治疗具有重要意义。

Structure-based design and biological evaluation of novel mTOR inhibitors as potential anti-cervical agents

The mammalian target of rapamycin(mTOR) is a critical component of the PI3K-AKT signaling pathway. It is highly activated in cervical cancer, which continues to pose an important clinical challenge with an urgent need for new and improved therapeutic approaches. Herein, we describe the structure-based drug discovery and biological evaluation of a series of m TOR kinase inhibitors as potential anti-cervical cancer agents. The results of enzymatic activity assays supported C3 as a potential m TOR inhibitor, which exhibited high inhibitory activity with an IC50 of 1.57 μM. Molecular docking and dynamics simulation were conducted to predict the binding patterns, suggesting relationships between structure and activity. The anti-proliferative assay against diverse cancer cell lines was displayed subsequently, revealing that C3 exhibited significant proliferation inhibition against cervical cancer cell He La(IC50=0.38μM) compared with other cell lines. Moreover, C3 could effectively reduce the expression of phospho-ribosomal S6 protein(p-S6) in He La cells in a dose-dependent manner. Noteworthily, m TOR signaling and other cellular pathways might contribute to the significant effect of C3 against cervical cancer simultaneously. These data indicated that C3 represented a good lead molecule for further development as a therapeutic agent for cervical cancer treatment.